Bluebird: Can It Keep Singing?
November 06, 2017 at 15:04 PM EST
Talk about a sudden about-face. Less than a month ago, Evercore ISI analyst Josh Schimmer upgraded Bluebird bio (BLUE) to an Outperform and raised his price target to $152 a share. Getty Images Today, Schimmer returned to the sidelines on the gene therapy company. He downgraded the stock to an In-Line, noting that Bluebird’s share price spiked […]